

SCIENTIFIC SEMINARS
INTERNATIONAL FOUNDATION

Education in Breast Cancer

Clinical Updates in Advancements of Treatment of TNBC, HR+, HER2+, HER2-Low Breast Cancer: ESMO Congress Updates

OVERVIEW

The aim of this educational curriculum is to present and evaluate latest breakthroughs, therapies, and strategies in Breast Cancer (BC) management that have transformed the approach to this complex and chronic condition.
The two self-study modules are designed to offer a thorough understanding of the wide range of treatment modalities available.
From conventional methods to cutting-edge innovations, providing insights on BC management optimization, including the use of Antibody Drug Conjugates (ADCs), immunotherapy, Parp-inhibitors and a potential therapeutic algorithm for HER2-low breast cancer.

LEARNING OBJECTIVES

- Assess the efficacy and safety of treatment approaches, especially antibody-drug conjugates plus immunotherapy, in the management of patients with mBC, with and implications for team-based and shared decision-making globally
- Apply the most recent evidence-based recommendations on use of ADCs when managing patients with HER2+, HR+, HER2-Low and TNBC based on specific patient and tumor characteristics
- Discuss the most recent evidence-based recommendations and guidelines on the role of antibody-drug conjugates, with focus on safety, in the management of patients with mBC.

TARGET AUDIENCE

Oncology clinicians, surgeons and healthcare professionals specifically those actively involved in the management and treatment of breast cancer.

LANGUAGE

The two self-study modules are in English with speaking notes in French, German, Italian, Spanish and Japanese.

MEDICAL ADVISOR

Francesco Pantano
Campus Biomedico Roma
Rome, Italy

ESMO CONGRESS 2024 HIGHLIGHTS ARE AVAILABLE

REGISTRATION FREE OF CHARGE

COURSES AVAILABLE IN MULTIPLE LANGUAGES:

CLICK HERE TO ACCESS YOUR COURSE

CME ACCREDITATION

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates each self-study module with:

- For a maximum of 0.5 AMA PRA Category 1 Credit™
- For a maximum of 0.5 CNE contact hour (0.5 CNE pharmacotherapeutic contact hours).
- 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education

The e-learning activities “Defining the therapeutic algorithm in patients with HR positive breast cancer” and “Antibody Drug Conjugates (ADCs)” are accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists.

U.E.M.S. EACCME

SCIENTIFIC SEMINARS INTERNATIONAL FOUNDATION · academicCME · AXDEV · REALCME

Endorsed by the European Society for Radiotherapy and Oncology

Endorsed by ESTRO

Endorsed by the European Oncology Nursing Society

Scientific Seminars International Foundation
education@scientificseminars.com

This educational program is made possible thanks to an unrestricted educational grant from Daiichi Sankyo Inc.